
In a post-hoc sub-analysis of the EMBLEM trial, focusing on Japanese patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), the impact of empagliflozin on blood pressure was investigated. Results showed a significant reduction in systolic and diastolic blood pressures, as well as mean arterial pressure, compared to the placebo group over 24 weeks. The mean differences in these parameters were -5.9 mmHg, -2.9 mmHg, and -3.8 mmHg, respectively. Notably, the reduction in systolic blood pressure remained consistent across various patient characteristics and the use of antihypertensive medications. These findings shed light on the potential cardiovascular benefits of empagliflozin in high-risk Japanese patients with T2D.
Like
Save
Share